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Circulating cell-free DNA (ccfDNA) in the plasma of
cancer patients constitutes a potential source of tumor-
derived DNA. Sensitive mutation detection assays on
ccfDNA extracted from plasma could be used to detect
circulating tumor DNA (ctDNA). This poses opportu-
nities to apply ctDNA as an easily accessible biomarker
for cancer screening, predictive testing, and monitoring
of disease and treatment responses (Heitzer et al., 2019;
Lampignano et al., 2019; Pantel and Alix-Panabieres,
2019). However, blood-based molecular tumor profiling
has been approached with caution since the origin of
the detected variants is uncertain. CcfDNA consists of
mostly degraded DNA fragments shedded from various
tissues through apoptosis, necrosis, exocytose, or active
secretion, of which over 90% derives from the hemato-
logical lineage (Abbosh, Birkbak, and Swanton, 2018;
Thierry et al., 2016; Xia et al., 2017). High-sensitive
mutation detection methods using ccfDNA from cancer
patients demonstrated a low overall yield of total DNA
and that the ctDNA fraction accounts only for a very
small proportion of the total ccfDNA of less than 0.1–
1%. This fraction varies significantly according stage of
disease, response to treatment, tumor burden, and
tumor characteristics such as tumor grade, vasculariza-
tion, cell death, and proliferation rates (Heitzer et al.,
2019). Since the ctDNA fraction is extremely low in
many cancers, ctDNA detection methods are required
to be highly sensitive and highly specific (Elazezy and
Joosse, 2018; Merker et al., 2018). Recent developments
in high-sensitive, more sophisticated sequencing
methodologies to detect tumor-derived mutations in
ctDNA enabled to identify variants that are present at
very low levels in a background of ‘normal’ ccfDNA
using, for example, combinations of integrated digital
error suppression (like unique-molecular-identifier),
appropriate variant calling, multigene analysis, and in-
depth sequencing (Abbosh et al., 2018; Heitzer et al.,
2019; Razavi et al., 2019).
In this issue, Kruger and colleagues determined the
presence of hotspot mutations and ctDNA load using a
high-sensitive sequencing 10-gene panel approach to
describe treatment outcome in estrogen receptor (ER)-
positive, HER2-negative metastatic breast cancer
(MBC) patients treated with everolimus and exemestane
(EVE/EXE) (Kruger et al., 2020). In this study, 76% of
the included MBC patients were considered ctDNA pos-
itive with a high prevalence of ESR1, PIK3CA, and
TP53 variants. A shorter progression-free survival
(PFS) was found in patients with three or more muta-
tions (P = 0.003) or with 54 or more mutant ctDNA
copies (P = 0.002). A recent study on a comparable
cohort showed similar associations between high quanti-
ties of ctDNA and a diminished survival (Suppan et al.,
2019). The study of Kruger and colleagues is one of the
first to demonstrate the potential of ctDNA mutation
testing using pretreatment plasma to select patients with
ER-positive/HER2-negative MBC eligible for EVE/
EXE with prolonged PFS and that high-sensitive
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sequencing of ccfDNA might support predicting treat-
ment response in MBC.
In addition, the analysis revealed that certain (likely)
pathogenic mutations in ESR1 and SF3B1 might affect
PFS and OS as well (P = 0.084 and P = 0.088). In line
with previous reports, specific ESR1 mutations such as
Y537S were considered as adverse prognostic biomark-
ers while other mutations, like in PIK3CA, do not
affect PFS (Moynahan et al., 2017; Reinert et al.,
2017). Besides, in a similar cohort using a larger gene
panel, other specific mutations in AR, MUC16, and
ERBB2 (not tested in the Kruger study) revealed that
each separately had a significant association with sur-
vival in MBC (Keup et al., 2019). These findings imply
that not just the number of observed different hotspot
mutations might be associated with treatment response
in MBC, but the presence or absence of certain strongly
pathogenic mutations such as ESR1 or MUC16 might
influence survival significantly. Therefore, future experi-
ments of larger cohorts are needed to evaluate the con-
tribution of these separate pathogenic mutations in
combination with the total number of other mutations
on clinical outcome to further improve the value of
ctDNA testing as a predictive biomarker for survival.
An important drawback of the implementation of
innovative high-sensitive ccfDNA sequencing
approaches is the detection of variants that are not
derived from the vital tumor cells. Some of these vari-
ants are the result of technical artifacts during
ccfDNA sequence analysis. This was recently illus-
trated when comparing 4 different commercially avail-
able next-generation sequencing methodologies with
considerable high discordances reflected in many false-
positive and false-negative results (Stetson et al.,
2019). Other insignificant variants appear due to inap-
propriate variant calling resulting from inaccurate dis-
crimination of somatic tumor-relevant variants from
SNPs, germ-line mutations, sequencing artifacts, clonal
hematopoiesis of indeterminate potential (CHIP)
among others. All these inappropriate variant callings
may confound the interpretation of ccfDNA sequenc-
ing in particular when applied to investigate associa-
tions with tumor response and clinical outcome.
Clonal hematopoiesis of indeterminate potential is
the consequence of the accumulation of somatic muta-
tions resulting from replication errors in the rapidly
dividing and mutation-prone hematopoietic progenitors
(Gondek and DeZern, 2020; Razavi et al., 2019). These
somatic mutations may provide a selective benefit to
some hematopoietic stem cells and their progenitors,
resulting in their disproportionate expansion. Since the
majority of ccfDNA is blood cell-derived, somatic
mutations associated with CHIP can thus be detected
during ccfDNA sequencing analysis (Gondek and
DeZern, 2020; Razavi et al., 2019). Indeed, Chen and
coworkers detected somatic mutations in the ccfDNA
in 30% of healthy aging individuals in genes related to
hematological malignancies including TP53 (Chen
et al., 2019). Razavi and associates using high-intensity
sequencing with 401-gene panel reported that most
somatic mutations detected in control patients without
cancer (81.6%) were also identified in their matched
white blood cells (WBC) (Razavi et al., 2019). Similarly,
most mutations identified in ccfDNA samples of cancer
patients (including MBC) were also found in their
matched WBC (53.2%). Furthermore, the number of
WBC-matched ccfDNA variants in cancer patients did
not correlate with the number of tumor biopsy-matched
mutations. All these specific somatic mutations are less
likely to be of tumor origin and have features consistent
with CHIP (Razavi et al., 2019).
In summary, the recent achievements in high-sensitive
sequencing methodologies of pretreatment plasma
ccfDNA have proven to become an useful tool to detect
and map tumor-derived mutations and offer opportuni-
ties as those reported by Kruger and colleagues, to
investigate the clinical value for the prediction of ther-
apy response and clinical outcome. However, these same
high-sensitive sequencing methodologies now also visu-
alize that most variants detected in ccfDNA of cancer
patients represent especially CHIP and that CHIP is
more prevalent than was previously anticipated (Chen
et al., 2019; Razavi et al., 2019). In particular, this high
prevalence of CHIP emphasizes the importance of par-
allel high-sensitive sequencing of DNA derived from
WBCs of the same patient for appropriate variant inter-
pretation.
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